BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 15067353)

  • 1. Specific tumour localisation of a huA33 antibody--carboxypeptidase A conjugate and activation of methotrexate-phenylalanine.
    Deckert PM; Bornmann WG; Ritter G; Williams C; Franke J; Keilholz U; Thiel E; Old LJ; Bertino JR; Welt S
    Int J Oncol; 2004 May; 24(5):1289-95. PubMed ID: 15067353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate-alpha-phenylalanine: optimization of methotrexate prodrug for activation by carboxypeptidase A-monoclonal antibody conjugate.
    Vitols KS; Haag-Zeino B; Baer T; Montejano YD; Huennekens FM
    Cancer Res; 1995 Feb; 55(3):478-81. PubMed ID: 7834611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein.
    Hao XK; Liu JY; Yue QH; Wu GJ; Bai YJ; Yin Y
    Prostate; 2006 Jun; 66(8):858-66. PubMed ID: 16491483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.
    Wolfe LA; Mullin RJ; Laethem R; Blumenkopf TA; Cory M; Miller JF; Keith BR; Humphreys J; Smith GK
    Bioconjug Chem; 1999; 10(1):38-48. PubMed ID: 9893962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
    Almqvist Y; Steffen AC; Tolmachev V; Divgi CR; Sundin A
    Nucl Med Biol; 2006 Nov; 33(8):991-8. PubMed ID: 17127172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenografts.
    Deckert PM; Jungbluth A; Montalto N; Clark MA; Finn RD; Williams C; Richards EC; Panageas KS; Old LJ; Welt S
    Int J Cancer; 2000 Aug; 87(3):382-90. PubMed ID: 10897044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil).
    Tschmelitsch J; Barendswaard E; Williams C; Yao TJ; Cohen AM; Old LJ; Welt S
    Cancer Res; 1997 Jun; 57(11):2181-6. PubMed ID: 9187118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of methotrexate-phenylalanine by monoclonal antibody--carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro.
    Perron MJ; Page M
    Br J Cancer; 1996 Feb; 73(3):281-7. PubMed ID: 8562331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft.
    Barendswaard EC; Humm JL; O'Donoghue JA; Sgouros G; Finn RD; Scott AM; Larson SM; Welt S
    J Nucl Med; 2001 Aug; 42(8):1251-6. PubMed ID: 11483688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate.
    Smith GK; Banks S; Blumenkopf TA; Cory M; Humphreys J; Laethem RM; Miller J; Moxham CP; Mullin R; Ray PH; Walton LM; Wolfe LA
    J Biol Chem; 1997 Jun; 272(25):15804-16. PubMed ID: 9188478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of methotrexate-alpha-alanine by carboxypeptidase A-monoclonal antibody conjugate.
    Haenseler E; Esswein A; Vitols KS; Montejano Y; Mueller BM; Reisfeld RA; Huennekens FM
    Biochemistry; 1992 Jan; 31(3):891-7. PubMed ID: 1731945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution and efficacy of [131I]A33scFv::CDy, a recombinant antibody-enzyme protein for colon cancer.
    Panjideh H; Da Silva Coelho VC; Dernedde J; Bachran C; Förster GJ; Franke J; Fasold P; Fuchs H; Thiel E; Deckert PM
    Int J Oncol; 2008 Apr; 32(4):925-30. PubMed ID: 18360720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-alpha-peptide prodrugs.
    Hamstra DA; Pagé M; Maybaum J; Rehemtulla A
    Cancer Res; 2000 Feb; 60(3):657-65. PubMed ID: 10676650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of methotrexate alpha-peptides as prodrugs for activation by enzyme-monoclonal antibody conjugates.
    Huennekens FM
    Adv Enzyme Regul; 1997; 37():77-92. PubMed ID: 9381987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice.
    Barendswaard EC; Scott AM; Divgi CR; Williams C; Coplan K; Riedel E; Yao TJ; Gansow OA; Finn RD; Larson SM; Old LJ; Welt S
    Int J Oncol; 1998 Jan; 12(1):45-53. PubMed ID: 9454885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of methotrexate-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumor.
    Deguchi T; Chu TM; Leong SS; Horoszewicz JS; Lee CL
    Cancer Res; 1986 Aug; 46(8):3751-5. PubMed ID: 3731053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and characterization of human pancreatic preprocarboxypeptidase A1 and preprocarboxypeptidase A2.
    Laethem RM; Blumenkopf TA; Cory M; Elwell L; Moxham CP; Ray PH; Walton LM; Smith GK
    Arch Biochem Biophys; 1996 Aug; 332(1):8-18. PubMed ID: 8806703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake.
    Scott AM; Lee FT; Jones R; Hopkins W; MacGregor D; Cebon JS; Hannah A; Chong G; U P; Papenfuss A; Rigopoulos A; Sturrock S; Murphy R; Wirth V; Murone C; Smyth FE; Knight S; Welt S; Ritter G; Richards E; Nice EC; Burgess AW; Old LJ
    Clin Cancer Res; 2005 Jul; 11(13):4810-7. PubMed ID: 16000578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
    Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
    Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models.
    Meyer DL; Jungheim LN; Law KL; Mikolajczyk SD; Shepherd TA; Mackensen DG; Briggs SL; Starling JJ
    Cancer Res; 1993 Sep; 53(17):3956-63. PubMed ID: 8358723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.